XML 97 R76.htm IDEA: XBRL DOCUMENT v3.6.0.2
Segment Information Segment Information (Details) - USD ($)
$ in Millions
3 Months Ended 12 Months Ended
Dec. 31, 2016
Sep. 30, 2016
Jun. 30, 2016
Mar. 31, 2016
Dec. 31, 2015
Sep. 30, 2015
Jun. 30, 2015
Mar. 31, 2015
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Segment Reporting Information [Line Items]                      
Depreciation and amortization                 $ 1,496.6 $ 1,427.7 $ 1,379.0
Revenue $ 5,760.5 $ 5,191.7 $ 5,404.8 $ 4,865.1 $ 5,375.6 $ 4,959.7 $ 4,978.7 $ 4,644.7 21,222.1 19,958.7 19,615.6
Other Revenue, Net                 833.7 808.1 788.4
Long-Lived Assets [1] 8,994.5       8,696.6       8,994.5 8,696.6 8,547.2
Asset impairment, restructuring, and other special charges (147.6) (45.5) (58.0) (131.4) (144.9) (42.4) (72.4) (108.0) (382.5) (367.7) (468.7)
Selling, General and Administrative Expense                 (6,452.0) (6,533.0) (6,620.8)
Income before income taxes                 3,374.0 2,790.0 3,000.3
Cost of sales 1,466.0 1,400.9 1,465.0 1,323.0 1,389.2 1,236.9 1,218.4 1,192.7 5,654.9 5,037.2 4,932.5
Acquired in-process research and development (30.0) 0.0 0.0 0.0 (199.0) 0.0 (80.0) (256.0) (30.0) (535.0) (200.2)
Other-net, (income) expense 15.8 $ 27.2 $ 21.2 $ (149.0) 44.7 $ 86.5 $ (123.3) $ 92.7 (84.8) 100.6 340.5
Foreign Currency Transaction Gain (Loss), Realized                 (203.9) 0.0 0.0
Amortization of Intangible Assets                 687.9 631.8 535.9
Gains (Losses) on Extinguishment of Debt                 0.0 166.7 0.0
United States [Member]                      
Segment Reporting Information [Line Items]                      
Revenue [2]                 11,506.2 10,097.4 9,134.1
Long-Lived Assets [1] 4,984.6       4,576.8       4,984.6 4,576.8 4,566.2
Europe [Member]                      
Segment Reporting Information [Line Items]                      
Revenue [2]                 3,768.1 3,943.6 4,506.7
Long-Lived Assets [1] 2,140.7       2,306.4       2,140.7 2,306.4 2,401.5
JAPAN                      
Segment Reporting Information [Line Items]                      
Revenue [2]                 2,330.9 2,033.1 2,027.1
Long-Lived Assets [1] 92.4       89.2       92.4 89.2 80.4
Other Foreign Countries [Member]                      
Segment Reporting Information [Line Items]                      
Revenue [2]                 3,616.9 3,884.6 3,947.7
Long-Lived Assets [1] $ 1,776.8       $ 1,724.2       1,776.8 1,724.2 1,499.1
Human Pharmaceutical Products [Member]                      
Segment Reporting Information [Line Items]                      
Other Depreciation and Amortization                 723.4 720.7 790.0
Revenue                 18,063.9 16,777.7 17,269.0
Income before income taxes                 4,010.0 4,026.7 3,604.6
Total segment [Member]                      
Segment Reporting Information [Line Items]                      
Other Depreciation and Amortization                 813.3 801.5 848.8
Income before income taxes                 4,673.7 4,624.6 4,226.4
Animal Health Products [Member]                      
Segment Reporting Information [Line Items]                      
Other Depreciation and Amortization                 89.9 80.8 58.8
Revenue                 3,158.2 3,181.0 2,346.6
Income before income taxes                 663.7 597.9 621.8
Corporate, Non-Segment [Member]                      
Segment Reporting Information [Line Items]                      
Asset impairment, restructuring, and other special charges                 (382.5) (367.7) (468.7)
Selling, General and Administrative Expense                 0.0 0.0 (119.0)
Acquired in-process research and development                 (30.0) (535.0) (200.2)
Foreign Currency Transaction Gain (Loss), Realized                 (203.9) 0.0 0.0
Amortization of Intangible Assets                 (683.3) (626.2) (530.2)
Cymbalta [Member] | Human Pharmaceutical Products [Member]                      
Segment Reporting Information [Line Items]                      
Revenue [3]                 930.5 1,027.6 1,614.7
Humalog [Member] | Human Pharmaceutical Products [Member]                      
Segment Reporting Information [Line Items]                      
Revenue                 2,768.8 2,841.9 2,785.2
Humulin [Member] | Human Pharmaceutical Products [Member]                      
Segment Reporting Information [Line Items]                      
Revenue                 1,365.9 1,307.4 1,400.1
Forteo [Member] | Human Pharmaceutical Products [Member]                      
Segment Reporting Information [Line Items]                      
Revenue                 1,500.0 1,348.3 1,322.0
Evista [Member] | Human Pharmaceutical Products [Member]                      
Segment Reporting Information [Line Items]                      
Revenue                 172.4 237.3 419.8
Other Endocrinology [Member] | Human Pharmaceutical Products [Member]                      
Segment Reporting Information [Line Items]                      
Revenue                 913.6 696.4 672.9
Endocrinology [Member] | Human Pharmaceutical Products [Member]                      
Segment Reporting Information [Line Items]                      
Revenue                 8,082.8 7,036.8 6,939.0
Trajenta (BI) [Member]                      
Segment Reporting Information [Line Items]                      
Other Revenue, Net                 436.6 356.8 328.8
Trajenta (BI) [Member] | Human Pharmaceutical Products [Member]                      
Segment Reporting Information [Line Items]                      
Other Revenue, Net                 436.6 356.8 328.8
Trulicity [Member] [Member] | Human Pharmaceutical Products [Member]                      
Segment Reporting Information [Line Items]                      
Revenue                 925.5 248.7 10.2
Zyprexa [Member] | Human Pharmaceutical Products [Member]                      
Segment Reporting Information [Line Items]                      
Revenue                 725.3 940.3 1,037.3
Strattera [Member] | Human Pharmaceutical Products [Member]                      
Segment Reporting Information [Line Items]                      
Revenue                 854.7 784.0 738.5
Other Neuroscience [Member] | Human Pharmaceutical Products [Member]                      
Segment Reporting Information [Line Items]                      
Revenue                 209.8 183.5 206.0
Other Pharmaceuticals [Member] | Human Pharmaceutical Products [Member]                      
Segment Reporting Information [Line Items]                      
Revenue                 313.6 227.7 287.0
Alimta [Member] | Human Pharmaceutical Products [Member]                      
Segment Reporting Information [Line Items]                      
Revenue                 2,283.3 2,493.1 2,792.0
Erbitux [Member]                      
Segment Reporting Information [Line Items]                      
Revenue                 687.0 485.0 373.3
Other Revenue, Net                 100.0 309.4 327.2
Erbitux [Member] | Human Pharmaceutical Products [Member]                      
Segment Reporting Information [Line Items]                      
Revenue                 687.0 485.0 373.3
Cyramza [Member] | Human Pharmaceutical Products [Member]                      
Segment Reporting Information [Line Items]                      
Revenue                 614.1 383.8 75.6
Other Oncology [Member] | Human Pharmaceutical Products [Member]                      
Segment Reporting Information [Line Items]                      
Revenue                 137.4 147.9 152.1
Oncology [Member] | Human Pharmaceutical Products [Member]                      
Segment Reporting Information [Line Items]                      
Revenue                 3,721.8 3,509.8 3,393.0
Cialis [Member] | Human Pharmaceutical Products [Member]                      
Segment Reporting Information [Line Items]                      
Revenue                 2,471.6 2,310.7 2,291.0
Effient [Member] | Human Pharmaceutical Products [Member]                      
Segment Reporting Information [Line Items]                      
Revenue                 535.2 523.0 522.2
Other Cardiovascular [Member] | Human Pharmaceutical Products [Member]                      
Segment Reporting Information [Line Items]                      
Revenue                 218.6 234.3 240.3
Cardiovascular [Member] | Human Pharmaceutical Products [Member]                      
Segment Reporting Information [Line Items]                      
Revenue                 3,225.4 3,068.0 3,053.5
BI compounds [Member]                      
Segment Reporting Information [Line Items]                      
Other-net, (income) expense                     92.0
BI compounds [Member] | Corporate, Non-Segment [Member]                      
Segment Reporting Information [Line Items]                      
Other-net, (income) expense                 0.0 0.0 92.0
Neuroscience [Member] | Human Pharmaceutical Products [Member]                      
Segment Reporting Information [Line Items]                      
Revenue                 $ 2,720.3 $ 2,935.4 $ 3,596.5
Minimum [Member] | Sales Revenue, Goods, Net [Member]                      
Segment Reporting Information [Line Items]                      
Concentration Risk, Percentage                 11.00% 9.00% 8.00%
Minimum [Member] | Accounts Receivable [Member]                      
Segment Reporting Information [Line Items]                      
Concentration Risk, Percentage                 14.00% 12.00%  
Maximum [Member] | Sales Revenue, Goods, Net [Member]                      
Segment Reporting Information [Line Items]                      
Concentration Risk, Percentage                 17.00% 14.00% 14.00%
Maximum [Member] | Accounts Receivable [Member]                      
Segment Reporting Information [Line Items]                      
Concentration Risk, Percentage                 21.00% 16.00%  
Adjustment to Return Reserve [Member] | Cymbalta [Member] | Human Pharmaceutical Products [Member]                      
Segment Reporting Information [Line Items]                      
Revenue                 $ 175.0    
Fair Value Adjustment to Inventory [Member] | Corporate, Non-Segment [Member]                      
Segment Reporting Information [Line Items]                      
Cost of sales                 0.0 $ (153.0) $ 0.0
Long-term Debt [Member] | Corporate, Non-Segment [Member]                      
Segment Reporting Information [Line Items]                      
Other-net, (income) expense [4]                 $ 0.0 $ (152.7) $ 0.0
[1] (2) Long-lived assets consist of property and equipment, net, and certain sundry assets.
[2] (1) Revenue is attributed to the countries based on the location of the customer.
[3] (1) Cymbalta revenues benefited from reductions to the reserve for expected product returns of approximately $175 million during the year ended December 31, 2016.
[4] (2) We recognized pretax net charges of $152.7 million for the year ended December 31, 2015, attributable to the debt extinguishment loss of $166.7 million from the purchase and redemption of certain fixed-rate notes, partially offset by net gains from non-hedging interest rate swaps and foreign currency transactions associated with the related issuance of euro-denominated notes.